Ultragenyx Pharmaceutical, Inc. is a leading pharmaceutical company based in the United States, specializing in developing innovative treatments for rare and ultra-rare diseases. With a focus on environment, sustainability, and governance, this company offers a low-risk investment opportunity with an ESG score of 18.0. Ultragenyx's product portfolio includes Crysvita, Dojolvi, and Mepsevii, which provide treatment for various genetic diseases.